Market Cap 35.31M
Revenue (ttm) 0.00
Net Income (ttm) -29.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,882,900
Avg Vol 7,114,360
Day's Range N/A - N/A
Shares Out 115.06M
Stochastic %K 13%
Beta -0.02
Analysts Strong Sell
Price Target $4.81

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology
Sector: Healthcare
Phone: 408-501-8881
Fax: 408-904-6270
Address:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States
SaySomethingNice
SaySomethingNice Dec. 29 at 3:03 AM
$RVPH So, a biotech company that FDA WANT ANOTHER P3 CLINICAL TRIAL ahead.. And, THE SP IS AT .30-40 PPS LEVELS? Let me repeat here.. PHASE3 FDA WANT! This is worth at least $1+ pps ahead at MINIMUM easily! - IMO
0 · Reply
Ieatpaint123
Ieatpaint123 Dec. 29 at 1:11 AM
$RVPH Overnight price is .32 and climbing
1 · Reply
Ieatpaint123
Ieatpaint123 Dec. 28 at 7:55 PM
$RVPH My analysis suggests that a "pump" on Monday, December 29, 2025, is a distinct possibility, driven by technical indicators that suggest the stock is oversold, combined with strong analyst support and an extremely high short interest making it vulnerable to a squeeze. It is in effect a "coiled spring"
0 · Reply
Ieatpaint123
Ieatpaint123 Dec. 28 at 7:48 PM
$RVPH Based on the stock’s reaction to recent regulatory setbacks, a hypothetical estimate suggests short interest in RVPH likely increased to approximately 35–40 million shares by the end of December 2025. This would represent a 35–55% increase from the December 15 reported figure of 25.64 million shares. The primary danger in shorting RVPH right now lies not in its current low price or recent news, but in the potential for a sudden, sharp reversal (short squeeze) driven by its extremely high short interest and the inherent volatility of the biotech sector.
0 · Reply
Ieatpaint123
Ieatpaint123 Dec. 28 at 6:57 PM
$RVPH I'll be holding even after the short squeeze. Possible Buyout Event (2026–2028) The Karuna Parallel: Bristol Myers Squibb acquired Karuna for $14 billion in 2023, paying a 53% premium because they wanted a "first-in-class" treatment with a differentiated safety profile (no weight gain or motor issues). Reviva’s Path: Brilaroxazine is also differentiated by its favorable safety profile (minimal weight gain or metabolic issues). Once RECOVER-2 succeeds and an NDA is submitted, Reviva becomes an attractive target for companies like AbbVie or Pfizer that need to bolster their neuroscience pipelines to compete with BMS's KarXT. Market Cap ~$37 Million (Distressed) Stock Price ~$0.30 $4.00–$16.00+ (Analyst Target Range)
1 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Dec. 28 at 6:39 PM
$RVPH 😂😂😂😂
0 · Reply
Uphillskier
Uphillskier Dec. 28 at 12:38 AM
$RVPH pure speculation on my part but I asked AI if this was feasible: Reviva is currently in a "make or break" position regarding its drug brilaroxazine for schizophrenia. • The Situation: In December 2025, the FDA recommended a second Phase 3 trial (RECOVER-2) before an NDA submission. Reviva has stated they plan to start this in H1 2026, subject to sufficient financing. • Feasibility of a Royalty Deal: High. Royalty firms (like Royalty Pharma or Sagard) typically look for Phase 3-ready assets with clear regulatory pathways. Since Reviva already has one successful Phase 3 under its belt, they are a prime candidate for a "synthetic royalty" where they sell a percentage of future sales for upfront cash to fund the next trial. • The Trade-off: Reviva would likely have to give up a significant chunk of future revenue (e.g., 5–10%) to get the ~$50M$100M needed for a global Phase 3.
3 · Reply
Big79979
Big79979 Dec. 27 at 10:58 PM
$RVPH Get down...
0 · Reply
GI197845
GI197845 Dec. 27 at 7:32 PM
$RVPH It does not take a genius to realize Lax Bhat is a con-artist. Sadly, we will be completely wiped out either sooner or later. Since this is not a real biotech, he will r/s and mass dilute, to stretch out his earnings for as long as possible. Is there anything legally stopping him from selling his shares now and the next day doing, an r/s and diluting and then maybe buying the shares back later, or just issuing himself more shares just because, he can? I would rather he sell the company, but I don't think there are any offers, because big pharma thinks he's a con-artist. If there was an offer, he's so greedy, that I don't think he'd sell, even if there was a decent buy out offer. I think this was always, only intended to be a lifestyle company to fund his rich lifestyle. Sadly, these types of biotech scams happen all the time.
4 · Reply
GI197845
GI197845 Dec. 27 at 7:09 PM
$RVPH https://www.youtube.com/watch?v=GoULsV4ur3c
1 · Reply
Latest News on RVPH
Top 3 Health Care Stocks That May Explode In September

Sep 19, 2025, 7:01 AM EDT - 3 months ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX


Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 8:00 AM EST - 11 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference


Reviva Announces Proposed Public Offering

Dec 16, 2024, 5:18 PM EST - 1 year ago

Reviva Announces Proposed Public Offering


Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference


Reviva to Participate in the BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention


Reviva to Present at the UBS Virtual CNS Day

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present at the UBS Virtual CNS Day


Reviva to Present at the 36th Annual ROTH Conference

Mar 7, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at the 36th Annual ROTH Conference


SaySomethingNice
SaySomethingNice Dec. 29 at 3:03 AM
$RVPH So, a biotech company that FDA WANT ANOTHER P3 CLINICAL TRIAL ahead.. And, THE SP IS AT .30-40 PPS LEVELS? Let me repeat here.. PHASE3 FDA WANT! This is worth at least $1+ pps ahead at MINIMUM easily! - IMO
0 · Reply
Ieatpaint123
Ieatpaint123 Dec. 29 at 1:11 AM
$RVPH Overnight price is .32 and climbing
1 · Reply
Ieatpaint123
Ieatpaint123 Dec. 28 at 7:55 PM
$RVPH My analysis suggests that a "pump" on Monday, December 29, 2025, is a distinct possibility, driven by technical indicators that suggest the stock is oversold, combined with strong analyst support and an extremely high short interest making it vulnerable to a squeeze. It is in effect a "coiled spring"
0 · Reply
Ieatpaint123
Ieatpaint123 Dec. 28 at 7:48 PM
$RVPH Based on the stock’s reaction to recent regulatory setbacks, a hypothetical estimate suggests short interest in RVPH likely increased to approximately 35–40 million shares by the end of December 2025. This would represent a 35–55% increase from the December 15 reported figure of 25.64 million shares. The primary danger in shorting RVPH right now lies not in its current low price or recent news, but in the potential for a sudden, sharp reversal (short squeeze) driven by its extremely high short interest and the inherent volatility of the biotech sector.
0 · Reply
Ieatpaint123
Ieatpaint123 Dec. 28 at 6:57 PM
$RVPH I'll be holding even after the short squeeze. Possible Buyout Event (2026–2028) The Karuna Parallel: Bristol Myers Squibb acquired Karuna for $14 billion in 2023, paying a 53% premium because they wanted a "first-in-class" treatment with a differentiated safety profile (no weight gain or motor issues). Reviva’s Path: Brilaroxazine is also differentiated by its favorable safety profile (minimal weight gain or metabolic issues). Once RECOVER-2 succeeds and an NDA is submitted, Reviva becomes an attractive target for companies like AbbVie or Pfizer that need to bolster their neuroscience pipelines to compete with BMS's KarXT. Market Cap ~$37 Million (Distressed) Stock Price ~$0.30 $4.00–$16.00+ (Analyst Target Range)
1 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Dec. 28 at 6:39 PM
$RVPH 😂😂😂😂
0 · Reply
Uphillskier
Uphillskier Dec. 28 at 12:38 AM
$RVPH pure speculation on my part but I asked AI if this was feasible: Reviva is currently in a "make or break" position regarding its drug brilaroxazine for schizophrenia. • The Situation: In December 2025, the FDA recommended a second Phase 3 trial (RECOVER-2) before an NDA submission. Reviva has stated they plan to start this in H1 2026, subject to sufficient financing. • Feasibility of a Royalty Deal: High. Royalty firms (like Royalty Pharma or Sagard) typically look for Phase 3-ready assets with clear regulatory pathways. Since Reviva already has one successful Phase 3 under its belt, they are a prime candidate for a "synthetic royalty" where they sell a percentage of future sales for upfront cash to fund the next trial. • The Trade-off: Reviva would likely have to give up a significant chunk of future revenue (e.g., 5–10%) to get the ~$50M$100M needed for a global Phase 3.
3 · Reply
Big79979
Big79979 Dec. 27 at 10:58 PM
$RVPH Get down...
0 · Reply
GI197845
GI197845 Dec. 27 at 7:32 PM
$RVPH It does not take a genius to realize Lax Bhat is a con-artist. Sadly, we will be completely wiped out either sooner or later. Since this is not a real biotech, he will r/s and mass dilute, to stretch out his earnings for as long as possible. Is there anything legally stopping him from selling his shares now and the next day doing, an r/s and diluting and then maybe buying the shares back later, or just issuing himself more shares just because, he can? I would rather he sell the company, but I don't think there are any offers, because big pharma thinks he's a con-artist. If there was an offer, he's so greedy, that I don't think he'd sell, even if there was a decent buy out offer. I think this was always, only intended to be a lifestyle company to fund his rich lifestyle. Sadly, these types of biotech scams happen all the time.
4 · Reply
GI197845
GI197845 Dec. 27 at 7:09 PM
$RVPH https://www.youtube.com/watch?v=GoULsV4ur3c
1 · Reply
SovereignMind
SovereignMind Dec. 27 at 2:13 AM
$RVPH I'm willing to bet, CURRENT to the day, short interest is over 60%. Some of these brokerage borrow rates are brutal. The stock has a relatively low float and MC right now. It might run Monday... Big Time
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 11:44 PM
$RVPH Share Price: $0.31 Contract Selected: Apr 17, 2026 $0.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 65% ROI Time to Expiration: 111 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Storm87
Storm87 Dec. 26 at 7:31 PM
$RVPH Almighty AI Compute Hypothetical Squeeze OddsWe calculate the Squeeze Likelihood Index (SLI) using the following formula:\(SLI=(S_{score}\times 0.4)+(D_{score}\times 0.4)+(B_{score}\times 0.2)\)\(SLI=(8\times 0.4)+(9\times 0.4)+(6\times 0.2)\)\(SLI=3.2+3.6+1.2=8.0\)Answer:The hypothetical odds of a short squeeze occurring for RVPH are 80%
1 · Reply
DARKP00L
DARKP00L Dec. 26 at 7:02 PM
$RVPH massive Volume Spike! In this stock is generating a lot of buzz today!
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 26 at 6:59 PM
$RVPH I hope that Bhat and Seems don’t plan on going back to India anytime soon, as they might get a stoning with the investors there!
0 · Reply
Gropius
Gropius Dec. 26 at 6:33 PM
$RVPH The question one might ask is this: Who bought around 76 million shares for about 30 cents each in the last three trading days? Sure, a lot of it is speculative and traded, but ultimately a huge number end up in a brokerage account. It's kind of fascinating!
0 · Reply
Gropius
Gropius Dec. 26 at 6:22 PM
$RVPH jgo1, thanks for the clarification! I only read the last 13 G and didn't pay attention to the total number. However, that doesn't change much.
0 · Reply
Gropius
Gropius Dec. 26 at 5:41 PM
$RVPH When I read that the share price is running down to the last options to be converted, it makes my stomach churn! According to the last 13G report, only 2 million shares out of 54 million options have been converted! If the options are really going to be converted, they would need a lot of buyers who are unaware of Reviva's financial situation and would buy 52 million shares and hope for a miracle. The next dilution would definitely be gigantic, as at least $60 million would be needed. At 15 cents, that would mean 400 million shares and at least 400 million options. In total, we'd be looking at a minimum of about one billion shares! Therefore, according to H.C. Wainwright's analysis, the sale or buyout would have to be worth $4 billion! That would be a very long way off! Better to find a buyer or partner now, because anything else is just wishful thinking.
2 · Reply
Storm87
Storm87 Dec. 26 at 5:11 PM
$RVPH Extremely bearish score of 10 on Stocktwits. Time to buy.
1 · Reply
SaySomethingNice
SaySomethingNice Dec. 26 at 4:35 PM
$RVPH I just read the news.. FDA didn't reject outright. FDA want to P3 trial amd some guidance protocal.. I mean, its biotech, nothing is easy. However, I do think the sp is severely undervalue, atm. Glta... - Imo
0 · Reply
jgo1
jgo1 Dec. 26 at 1:41 PM
$RVPH They're a lot of shares available to short this morning and before the negative FDA news dropped that would have signaled a positive price movement setting up new short positions at higher prices before dropping them again from October to pre NDA news. I bought just over 100k shares Wednesday on the drop to .2, maybe I'll add a few more on the gamble those controlling the warrants move this over .335 and in the money again, very short term trade for me. Looks like about 35 million .335 warrants out of the money and pre RS short positions may try to be set up is my bet for today.
2 · Reply
thatguyshaq
thatguyshaq Dec. 26 at 12:14 PM
Between $RVPH flipping on me and $AIRI burning me, I could do with a win before the year is out. Think $SIDU could run or it gonna sell off at open?
1 · Reply